Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesOxford Cannabinoid Technologies Holdings PLC

Oxford Cannabinoid Technologies Holdings PLC

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
None GBX 0.00(0%)
Last update at 2024-07-04T08:32:47.745373Z
Market Cap
7.20M

Momentum Score

…

Oxford Cannabinoid Technologies Holdings Plc, a pharmaceutical company, engages in the research, development, and commercialization of cannabinoid-based prescription medicines. Its lead drug candidate consists of OCT461201, an CB2 receptor, that is in phase " I clinical trial for use in the treatment of chemotherapy-induced peripheral neuropathy and irritable bowel syndrome (IBS), as well as in neuropathic and visceral pain conditions. The company is also developing OCT130401, which is in pre-clinical development for the treatment of trigeminal neuralgia. In addition, its development pipeline includes cannabinoid derivative products comprising OCT960609, a dual CB1 and CB2 agonist targeting an undisclosed neuropathic pain indications; and immunotherapy agents for the treatment of solid tumours. Oxford Cannabinoid Technologies Holdings Plc was incorporated in 2017 and is headquartered in London, the United Kingdom.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

52 Week Price Range
0.57
Low
1.60
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High

Key Metrics*

Previous Close
-
Dividend Yield
-
Revenue TTM
0.00M
Revenue Per Share
-
Gross Profit TTM
-4.30M
Debt / Equity
0.01
ROE
-86.76%
Net Debt
-2.30M
ROCE
-178.18%
Diluted EPS TTM
-0.01

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2023-04-30 2022-04-30 2021-05-31 2020-05-31 2019-05-31
Type yearly yearly yearly yearly yearly
Date 2023-04-30 2022-04-30 2021-05-31 2020-05-31 2019-05-31
Income before tax -7.03M -0.01M -3.37M -2.37M -2.88M
Net income -5.95M -0.01M -3.23M -2.14M -2.62M
Selling general administrative 2.67M 0.00M 1.52M - -
Gross profit -4.30M -0.00M -0.45M -1.24M -1.28M
Reconciled depreciation 0.04M - 0.16M 0.08M 0.00M
Ebit -6.97M -0.01M -2.94M -1.34M -1.28M
Ebitda -6.93M -0.01M -2.77M -1.26M -1.28M
Depreciation and amortization 0.04M 0.00M 0.16M 0.08M 0.00M
Operating income -7.04M -0.01M -3.35M -2.35M -2.77M
Other operating expenses 6.97M 0.00M 2.99M 2.35M 2.77M
Interest expense 0.00M - 0.07M 0.02M 0.02M
Tax provision -1.09M - -0.14M -0.23M -0.26M
Interest income 0.00M - 0.05M - -
Net interest income 0.00M - -0.02M -0.02M -0.02M
Income tax expense -1.09M 0.00M -0.14M -0.23M -0.26M
Total revenue 0.00M - 0.00M 0.00M 0.00M
Total operating expenses 2.67M 0.00M 2.54M 1.10M 1.49M
Cost of revenue 4.30M 0.00M 0.45M 1.24M 1.28M
Total other income expense net 0.00M -0.00M -0.00M -0.02M -0.11M
Net income from continuing ops -5.95M - -3.23M -2.14M -2.62M
Net income applicable to common shares -5.95M -5.14M -3.23M - -
Breakdown 2023-04-30 2022-04-30 2021-05-31 2020-05-31 2019-05-31
Type yearly yearly yearly yearly yearly
Date 2023-04-30 2022-04-30 2021-05-31 2020-05-31 2019-05-31
Total assets 4.50M 0.01M 15.21M 1.31M 2.33M
Intangible assets 0.01M 0.00M 0.10M 0.14M 0.14M
Other current assets - - 0.42M 0.71M 0.61M
Total liab 0.58M 0.00M 1.00M 0.78M 0.55M
Total stockholder equity 3.91M -0.00M 14.21M 0.53M 1.79M
Other current liab 0.30M 0.00M 0.00M 0.24M 0.23M
Common stock 9.60M 0.01M 9.60M 0.00M 0.00M
Capital stock 9.60M - 9.60M 0.00M 0.00M
Retained earnings -19.73M -0.01M -9.07M -5.89M -3.75M
Cash 2.30M 0.01M 14.63M 0.31M 1.65M
Total current liabilities 0.58M 0.00M 0.95M 0.73M 0.55M
Current deferred revenue - - 0.32M - -
Net debt -2.30M -0.01M -14.46M -0.31M -1.65M
Short term debt - - 0.13M - -
Short long term debt 0.00M - 0.00M - -
Short long term debt total - - 0.17M - -
Other stockholder equity 14.03M 0.00M 13.68M 6.42M 5.54M
Property plant equipment - - 0.06M - -
Total current assets 4.49M 0.01M 15.05M 1.02M 2.26M
Net tangible assets 3.90M 9.75M 14.11M - -
Net receivables 1.94M 1.13M 0.34M - -
Long term debt 0.00M - 0.05M - -
Accounts payable 0.29M 0.00M 0.50M 0.49M 0.31M
Non currrent assets other - -0.00M - -0.14M -0.14M
Non current assets total 0.01M 0.00M 0.16M 0.29M 0.07M
Capital lease obligations 0.00M - 0.12M - -
Breakdown 2023-04-30 2022-04-30 2021-05-31 2020-05-31 2019-05-31
Type yearly yearly yearly yearly yearly
Date 2023-04-30 2022-04-30 2021-05-31 2020-05-31 2019-05-31
Investments 0.00M - 0.05M -0.30M -0.16M
Change to liabilities -1.44M 1.17M 0.19M - -
Total cashflows from investing activities - 0.00M 0.05M - -
Net borrowings - -0.10M 0.63M - -
Total cash from financing activities - -0.00M 16.05M 0.75M 4.75M
Net income -5.95M -0.01M -3.23M -2.14M -2.62M
Change in cash -6.87M -0.01M 14.32M -1.34M 1.63M
Begin period cash flow 9.17M 0.01M 0.31M 1.65M 0.01M
End period cash flow 2.30M 9.17M 14.63M 0.31M 1.65M
Total cash from operating activities -6.87M -0.01M -1.78M -1.79M -2.95M
Issuance of capital stock - - 16.75M 0.75M 4.75M
Depreciation 0.04M 0.00M 0.16M 0.08M 0.00M
Other cashflows from investing activities - - 0.05M - -
Change to account receivables 1.33M -0.00M 0.00M - -
Other cashflows from financing activities - -0.00M -0.70M -0.30M -0.16M
Change to netincome -0.85M -0.43M 1.06M - -
Capital expenditures 0.00M 0.00M 0.00M 0.30M 0.08M
Change in working capital -0.11M -0.00M 0.22M -0.00M -0.20M
Stock based compensation 0.06M 0.00M 1.02M 0.14M 0.04M
Other non cash items -0.00M -0.00M 0.02M 0.02M 0.02M
Free cash flow -6.87M -0.01M -1.78M -2.09M -3.03M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(GBX)
Price
(GBX)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to EBITDA (x)
GNS
Genus PLC		 18.00
0.78%		 2340.00 36.08 26.18 2.53 3.46 15.38
ONT
Oxford Nanopore Technologies Ltd		 10.60
4.93%		 225.60 - - 4.71 2.50 -8.89
OXB
Oxford BioMedica PLC		 5.00
0.95%		 532.00 - 208.33 4.05 7.60 308.96
AVCT
Avacta Group PLC		 -1.00
1.60%		 61.50 - - 2849.46 1929.84 -12.04

Profile*

Oxford Cannabinoid Technologies Holdings PLC

Oxford Cannabinoid Technologies Holdings Plc, a pharmaceutical company, engages in the research, development, and commercialization of cannabinoid-based prescription medicines. Its lead drug candidate consists of OCT461201, an CB2 receptor, that is in phase " I clinical trial for use in the treatment of chemotherapy-induced peripheral neuropathy and irritable bowel syndrome (IBS), as well as in neuropathic and visceral pain conditions. The company is also developing OCT130401, which is in pre-clinical development for the treatment of trigeminal neuralgia. In addition, its development pipeline includes cannabinoid derivative products comprising OCT960609, a dual CB1 and CB2 agonist targeting an undisclosed neuropathic pain indications; and immunotherapy agents for the treatment of solid tumours. Oxford Cannabinoid Technologies Holdings Plc was incorporated in 2017 and is headquartered in London, the United Kingdom.

Maddox House, London, United Kingdom, W1S 2PZ

44 20 3034 2820

https://www.oxcantech.com

7

Name Title Year Born
Ms. Clarissa Ann Sowemimo-Coker Interim CEO, COO, Gen. Counsel, Company Sec. & Director 1981
Mr. Indraneil Mahapatra Co-Founder & Non-Exec. Director 1981
Dr. John Lucas Ph.D. Exec. Officer 1967
Eugenia Shostak Exec. Officer NA
Mr. Paul William Smalley Fin. Director & Director NA
Dr. Valentino Parravicini Chief Scientific Officer 1969

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

ORE
CAD 2.77
+8.86%
APM
CAD 4.95
+8.08%
NUAG
CAD 7.37
+8.06%
BZ
CAD 4.03
+8.04%
AYA
CAD 34.85
+7.96%
HUT
CAD 73.56
-17.26%
PHX
CAD 11.13
-12.22%
IVN
CAD 7.93
-10.70%
EFN
CAD 20.09
-10.39%
OBE
CAD 13.62
-6.71%

Equity Sectors*

  • Basic Materials

    +3.73%

  • Communication Services

    +1.16%

  • Consumer Cyclical

    +1.12%

  • Consumer Defensive

    +0.14%

  • Energy

    -1.87%

  • Financial Services

    +1.53%

  • Healthcare

    +1.50%

  • Industrials

    +0.03%

  • Real Estate

    +0.71%

  • Technology

    +0.40%

  • Utilities

    +0.35%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…